Graft vs Host Disease Clinical Trials in Hangzhou, Zhejiang
2 recruitingHangzhou, Zhejiang, China
Showing 1–2 of 2 trials
Recruiting
Phase 4
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
Graft vs Host DiseaseChronic Graft vs. Host DiseaseCorticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals50 enrolled22 locationsNCT06824103
Recruiting
Not Applicable
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
Graft vs Host Disease
First Affiliated Hospital of Zhejiang University122 enrolled1 locationNCT07184853